Herein we describe our experience with 75 consecutive autologous BM transplants for patients with high-risk ALL, with special attention to the clinical impact of BM purging. Fifty-two patients received purged BM using monoclonal antibody (MoAb) cocktails and complement, and 23 patients received untreated BM. The distribution of prognostic factors was similar in both groups. Hemopoietic reconstitution was adequate and did not differ in the two groups. Transplant-related mortality was 9.6% and 13% in 'purged' and 'unpurged' groups. Median follow up was 11 months (2-71) and overall actuarial probability of disease-free survival (DFS) at 5 years was 40% (53% relapse probability). We found a beneficial effect of purging in patients over 15 years of age and in patients needing more than 1 month to reach CR1. Patients in CR1 receiving purged marrow had a longer DFS and a lower relapse probability (52% vs 12%, P = 0.02 and 35% vs 86%, P = 0.005, respectively) which were related to the efficacy of the purging procedure (more or less than one log of depletion). In further CR, no advantage of purging has been found. Our data strongly suggest the clinical relevance of BM purging in autologous BMT in high-risk ALL patients and support the need for prospective randomized studies. Keywords: autologous BMT; acute lymphocytic leukemia; bone marrow purging Therapy for acute leukemia has become more and more efficient during the past decade. Most children with acute lymphoblastic leukemia (ALL) can be cured with current chemotherapy strategies.
inoside, etoposide, carboplatinum and other drugs in different combinations. [4] [5] [6] However, many of these AML patients and high-risk ALL patients will never be cured with chemotherapy due to the high incidence of relapse. 5, 6 Bone marrow transplantation (BMT) technologies have improved significantly over the past [15] [16] [17] [18] [19] [20] years and now constitute a regular therapeutic approach for poor-risk ALL patients. 7, 8 Although allogeneic BMT is currently curative for approximately 50% of the patients, [8] [9] [10] [11] [12] unfortunately, this kind of transplant can only be applied to those patients having an HLA-identical donor, either family related or unrelated. The probability of finding an HLA-matched donor in a family with at least two children is 25-30%, and unrelated donors can be found for 50% of patients who do not have a family donor. Also the probability of being in CR rapidly decreases during the first 4 to 5 months, which is the median time necessary for a successful search for an unrelated donor. Thus 40-50% of patients will not be eligible for this potentially curative therapeutic option.
Autologous BMT is an alternative to allogeneic BMT for many of these patients. 13, 14 There are at least two factors that make autologous BMT less likely to be curative when compared to allogeneic transplantation. First, the antileukemic effect of alloreactive-induced mechanisms in the context of graft-versus-host disease (GVHD) [15] [16] [17] is absent in autologous transplants. Second, contamination of the BM harvest by residual malignant cells potentially increases risk of disease relapse. [18] [19] [20] [21] Several new approaches to stimulating allo-or autoimmunity against the malignant proliferation are now ongoing in different studies, [22] [23] [24] [25] and efforts to eradicate any residual disease in the harvested marrow have been made using different techniques, some of them with controversial results. 26, 27 The aim of the present study was to retrospectively analyze the clinical impact of the ex vivo eradication of residual leukemic cells in harvested marrows from ALL patients using monoclonal antibodies and rabbit complement, showing that BM purging does not negatively affect hemopoietic reconstitution after autologous BMT and may improve DFS of ALL patients, especially those in first CR. 
Patients and methods
Seventy-five consecutive ALL patients autografted between January 1987 and June 1993 have been enrolled in this study, including children and adults recruited from three hospitals in Barcelona. All patients were autografted in CR.
Only those patients considered to be, at that time, at high risk of relapse were transplanted in first CR (CR1). High risk of relapse was defined as having one or more of the following features: age over 20 years, high leukocyte counts at diagnosis (more than 50 ϫ 10 9 /l), B or T cell markers in the leukemic population, slow response to standard treatment and central nervous system (CNS) involvement at diagnosis. All patients in second or further complete remission were also considered as candidates for autologous BMT.
Patients' harvested marrows were purged with monoclonal antibodies if the immunophenotype at diagnosis was available. The remaining patients, all of them referred from other centers, were transplanted with unpurged marrows.
From a total of 75 patients, 52 have been transplanted with purged marrow and 23 with unpurged marrow. The characteristics of both groups are shown in Table 1 . Both groups were not statistically different in terms of age, sex distribution, leukocyte count at diagnosis, intervals from diagnosis to CR and from CR to transplant, as well as the status of the disease at the time of transplant.
All patients received induction chemotherapy including vincristine, daunorubicin, prednisone and eventually lasparaginase. CNS prophylaxis, either with methotrexate (MTX) alone or in combination with holocranial irradiation, was applied in all cases. One or two courses of consolidation or intensification were given before autolog- ous BMT. Those patients not indicated for CR1 autologous BMT, or those waiting for the procedure, received maintenance with 6-mercaptopurine and MTX. The conditioning regimen for autologous BMT included CY (120 mg/kg in two daily consecutive doses) and TBI, 12 Gy in three Gy fractions administered on 4 consecutive days, 28 in 84% of the cases. The remaining cases, patients under 2 years of age and those in whom TBI was contraindicated due to previous irradiation, received BU (14 mg/kg total dose divided in four consecutive daily doses) and CY (120 mg/kg in two daily consecutive doses).
In patients for whom marrow was purged, the procedure was performed according to previously published techniques. 29 Briefly, bone marrow mononuclear cells (BMMNC) were obtained by density gradient centrifugation performed immediately after harvesting. These cells were incubated for 30 min with a cocktail of MoAbs against B cell (CD9, CD10, CD19 and CD20) or T cell lineage antigens (CD2, CD3, CD4, CD5, CD6 and CD8) according to the leukemic phenotype, followed by two cycles of 45 min incubation with rabbit serum as a source of complement (Pel-Freez, Brown Deer, WI, USA). The MoAbs employed were kindly provided by Dr P Martin (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). The efficiency of specific cell depletion was assessed by cytofluorometric analysis (EPICS Profile, Coulter, Hialeah, FL, USA), taking 0.1% as the threshold for sensitivity.
For statistical analysis the 2 test was used to compare variables across groups. The Kaplan and Meier method 30 was used to estimate the probability of DFS and relapse. Survival curves were compared with the log-rank test. The influence of prognostic factors on the outcome of the series was assessed by multivariate analysis using Cox's proportional hazards regression analysis. 31 
Results

Hemopoietic reconstitution and overall survival
The hematopoietic reconstitution of transplanted patients showed a slight delay, but the difference was not statistically significant in purged (n = 52) compared to unpurged (n = 23) patients (Table 2) .
Transplant-related mortality was 9.6% (five cases: two veno-occlusive disease (VOD), one interstitial pneumonitis, one disseminated aspergillus, one unknown) in the purged group and 13% (three cases: septicemia, VOD, CNS hemorrhage) in the unpurged group. The mean and median follow-up of surviving patients was 20 and 11 months, respectively (range 2-71 months). DFS at 5 years for the 623 Table 3 Disease-free survival distribution and log-rank test P values according to different prognostic factors Months DFS REL Figure 1 Actuarial disease-free survival for the whole group.
entire group was 40%, with a probability of relapse of 53% ( Figure 1 ). As shown in Table 3 , in the univariate analysis, age, sex, WBC count at diagnosis (over and under 50 ϫ 10 9 /l), time from diagnosis to CR (greater than 1 month), time from CR to autologous BMT (more than 6 months), status of the disease at time of autologous BMT (CRI vs others CR) and BM processing did not affect DFS significantly.
Impact of marrow purging on survival: univariate analysis
When the entire cohort of patients was considered, DFS at 3 years was 46.8% for purged patients and 25.6% for unpurged patients (log-rank test P = 0.13) and the probability of relapse at 3 years was 44.7% for purged patients and 70.6% for unpurged patients (log-rank test P = 0.12). When stratifying patients according to different classical predictive factors, we found data suggesting a positive influence of ex vivo treatment on survival (Table 4) . Thus, considering patients over 15 years of age, relapse probability at 3 years was higher in patients receiving unpurged marrow compared to those receiving purged marrow (87.5% vs 36.8% respectively) (P = 0.03).
Analyzing survival of patients, according to the time needed for obtaining a CR, patients needing more than 1 month showed a better DFS when transplanted with purged marrow (51.8%) than patients receiving untreated marrow (14.3%) (P = 0.02).
When patients were analyzed according to the time between CR (1st or later CR) and transplant, a statistically significant better survival in the purged group was observed for those patients remaining in CR for more than 6 months before transplant than for patients in CR for less than 6 months (56.4% vs 16.7% DFS and 38.3% vs 83.3% relapse rate, respectively).
The most interesting observation emerged when considering only first remission patients. When the actuarial probability of DFS and relapse were assessed according to purging, two different curves were obtained. Purged marrow CR1 patients had a DFS at 3 years of 52%, while those who received unpurged marrow only had a probability of DFS of 12% (P = 0.016) (Figure 2 ). Relapse probability was of 35% and 86%, respectively (P = 0.005).
Comparing patients in CR1 in whom purging was con- sidered satisfactory (more than 1 log depletion of the specific phenotype population: eight patients) with those in whom less than 1 log depletion was obtained (16 patients) , and with those in whom no purging was applied (eight patients), we obtained three different plots showing plateaus of 61%, 45% and 12.5% for DFS. When the impact of purging was considered in the cohort of CR2 patients, there was no evidence of any advantage of this procedure. In fact, 24 patients received purged marrow, while 11 received unpurged marrow. The probability of DFS at 66 and 54 months was 46% and 48%, respectively.
Impact of marrow purging on survival: multivariate analysis
Since previous univariate analyses failed to show any statistical significance for any predictive factors other than purging, multivariate analysis was restricted to this variable.
Thus, the purging factor was analyzed, sequentially adjusted for other variables such as transplant center, age, sex, LAL type, time from diagnosis to CR and time from CR to autologous BMT, according to the amount of data available. In all of these analyses marrow purging conferred a lower relapse risk to autotransplanted patients, especially among patients in CR1. This is highly significant considering the relatively low number of patients of this group. Confirmatory results of univariate analysis are shown in Table 5 . Table 5 Uni-and multivariate hazard ratio (HR) estimated for the effect of purging on relapse probability 
Discussion
Autologous BMT has become an alternative to traditional treatments for those patients who are not eligible for allogeneic BMT. Current estimates indicate that more than 2000 autologous BMT for leukemia are performed worldwide annually. 32 Autologous BMT used as salvage therapy for patients with acute leukemia in second or later CR shows a DFS ranging from 18 to 56%, with the major cause of failure being relapse of the disease ranging from 18 to 56%. 26, 33, 34 There are also several interesting experiences reported in first CR patients. Thus, analyzing nine different publications, DFS ranged from 32 to 56% at 2 years follow-up while relapse rates ranged from 11 to 62%, all them using unpurged marrow. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] One of the major controversial points of this procedure is the role of the residual disease remaining in the harvested marrow as responsible for relapse after autologous BMT. Some efforts have been made to treat harvested marrow in vitro to avoid reinfusion of leukemic stem cells. [43] [44] [45] [46] Most investigators have used derivates of CY (4-HC or mafosfamide) for in vitro purging of marrow and some of these experiences showed an improvement of the results in terms of DFS by diminishing the leukemic relapse rate (maximum relapse rate of 36%). 22, 29, 42, [47] [48] [49] [50] [51] [52] Results of autologous BMT in ALL differ from those in AML. Only very high-risk patients suffering from ALL are usually included in BMT programs even after second or further remissions. Furthermore, definition of high risk is very variable and controversial in this disease. The presence of the Philadelphia chromosome is universally accepted as a poor risk factor, but others such as leukocyte counts at diagnosis, phenotype of the leukemia cells, age, other cytogenetic abnormalities, remission duration time, extramedullary disease etc, are not universally accepted.
Nevertheless, the majority of studies published include patients after first relapse and the results in terms of DFS are relatively poor. Thus, the two studies of the Dana Farber Institute, one in children and one in adults, using purged marrow, have around 21% of DFS at 3 years observation. Kersey et al, 52 from the University of Minnesota, published their experience in a cohort of more than 150 cases, the majority of them in second or further CR, using purged marrow, and obtained a 21% DFS at 3 years of observation. Schmid et al, 46 from the Berlin group, reported their experience in a series of 22 children with ALL treated with auto-logous BMT using a three antibody cocktail for common ALL and B-ALL and a four antibody cocktail for T-ALL. Their experience resulted in 80% of relapses at 1 year and a DFS of 18%. The European Bone Marrow Transplantation multicenter retrospective study 47 in childhood ALL using mainly unpurged marrow obtained better results with DFS of 45% at 5 years. In contrast, the study in adults by the same group offered only a 20% DFS at 4 years of observation. 53 Another experience of autologous purged ALL marrow transplant has been published by Morishima et al. 50 In their series (17 cases), they controlled the efficacy of purging by polymerase chain reaction (PCR) techniques in some cases, including some Ph-positive ALL. This small but interesting study showed an excellent DFS of 75% at a maximum of 8 years follow-up for those patients transplanted in first CR. For patients in second or later CR, only one out of 10 was a disease-free survivor 4 years after autologous BMT. These authors suggested that purging with MoAb plus complement was effective by controlling bclabl before and after purging, and observing that, in the three Ph-positive patients, cells bearing that translocation disappeared after marrow purging. Nevertheless, that study did not have a control group of Ph-negative patients in first CR without purging.
Our experience reported in this paper differs from the previous studies in several aspects.
First, when the overall results are considered, we have a DFS of 47% at 1.5 years of observation time after transplant, with a plateau lasting 2160 days with only one relapse at day 900, whereas other series have a DFS around 20-25%.
Second, and maybe most important, when unpurged marrow transplanted patients treated with the same protocols of induction and consolidation as well as equally conditioned for autologous BMT are compared with purged marrow transplanted patients, we observe a different probability of staying in CR with a trend to statistical significance (P = 0.2). The same effect is observed when overall survival is considered. Thus, we can suggest that purging pathological clones of the harvested marrow with MoAb plus complement has a positive effect on the outcome of the patients. Furthermore, when only first CR patients are considered, these differences appear even more evident and are statistically significant (P = 0.03).
The role of purging in this subgroup of patients becomes more evident when the degree of purging is considered. When purging of the harvested marrow is more effective, a better DFS is achieved. This experience confirms and complements the experiences of some other authors investigating the value of the contamination of the inoculum in other models of lymphoproliferative disorders.
Interestingly, those experiences have not been observed in the groups of patients with second and later CR. We can speculate on two different reasons for this observation: firstly, a stronger in vivo purging due to additional chemotherapies are applied in this cohort of patients, and/or secondly, it might be that first remission patients having poor risk factors have a worse outcome than those of high risk due to relapse after first CR of so-called good risk patients. That is to say, relapse by itself is not as bad as B cell or T cell leukemia, age, leukocytosis at diagnosis or extramedullary involvement at diagnosis.
In conclusion, our data suggest that, at least, in CR1 patients with a poor risk diagnosis, eradication or reduction of residual leukemia in harvested and cryopreserved marrow is of benefit for the outcome in ALL autografts.
